Loading
A phase 3 trial of Glumetinib run by Shanghai JMT-Bio Inc. in non-small-cell lung cancer and small-cell lung cancer, now recruiting.
A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs is a phase 3 interventional study registered as NCT06829459 by Shanghai JMT-Bio Inc., with 350 participants planned, started 2025-04-03. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares CSPC Pharmaceutical Group, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Glumetinib, CSPC Pharmaceutical Group, Small-molecule kinase inhibitors.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares CSPC Pharmaceutical Group, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.
Shares CSPC Pharmaceutical Group, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.